BioLineRx Announces $40M Non-Dilutive Debt Financing Agreement With Kreos Capital
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that the Company has entered into a $40 million non-dilutive secured debt